Nurix Therapeutics (NASDAQ:NRIX) versus Xenon Pharmaceuticals (NASDAQ:XENE) Critical Contrast

Nurix Therapeutics (NASDAQ:NRIX) and Xenon Pharmaceuticals (NASDAQ:XENE) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Nurix Therapeutics and Xenon Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1	1	13	0	2.80
Xenon Pharmaceuticals	1	1	12	1	2.87

Nurix Therapeutics presently has a consensus target price of $34.79, suggesting a potential upside of 36.36%. Xenon Pharmaceuticals has a consensus target price of $70.14, suggesting a potential upside of 92.17%. Given Xenon Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than Nurix Therapeutics.

Valuation & Earnings

This table compares Nurix Therapeutics and Xenon Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98 million	33.19	-$264.46 million	$2.31	11.04
Xenon Pharmaceuticals	$7.50 million	470.46	-$345.91 million	($4.74)	-7.70

Nurix Therapeutics has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nurix Therapeutics and Xenon Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	42.01%	49.34%	38.61%
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%

Volatility & Risk

Nurix Therapeutics has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.

Institutional & Insider Ownership

95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 6.7% of Nurix Therapeutics shares are owned by insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Nurix Therapeutics beats Xenon Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

About Nurix Therapeutics

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.